The efficiency and safety of trastuzumab and lapatinib added to neoadjuvant chemotherapy in Her2-positive breast cancer patients: a randomized meta-analysis

BACKGROUND: The addition of human epidermal growth factor receptor 2 (Her2) therapies to neoadjuvant chemotherapy (NAC) during treatment of Her2-positive breast cancer has been proposed as an effective way to improve the prognosis. However, the treatment outcomes of adding trastuzumab, lapatinib, or...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Onco Targets Ther
Autori principali: Chen, Zhe-Ling, Shen, Yan-Wei, Li, Shu-Ting, Li, Chun-Li, Zhang, Ling-Xiao, Yang, Jiao, Lv, Meng, Lin, Ya-Yun, Wang, Xin, Yang, Jin
Natura: Artigo
Lingua:Inglês
Pubblicazione: Dove Medical Press 2016
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4892834/
https://ncbi.nlm.nih.gov/pubmed/27313469
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S106055
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi